Cryo-Cell International, Inc. (CCEL) - 10-K Summary
Business Context and Reporting Period
Company: Cryo-Cell International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: November 30, 2024
Business Overview: Cryo-Cell operates three primary segments: (1) cellular processing and cryogenic storage of umbilical cord blood and tissue for family use; (2) manufacturing of the PrepaCyte CB Processing System; and (3) public cord blood banking. The company stores over 240,000 specimens globally. Operations are headquartered in Oldsmar, Florida, with a major storage facility in Durham, North Carolina.
Key Financial Metrics
| Metric | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Total Revenue | $31,986,106 | $31,343,695 |
| Net Income (Loss) | $402,095 | $(9,521,669) |
| Operating Income (Loss) | $3,480,284 | $(12,304,032) |
| Cost of Sales | $7,947,752 | $8,390,463 |
| Operating Cash Flow | $6,010,910 | $8,919,754 |
| Cash and Equivalents (End of Period) | $560,960 | $406,067 |
| Total Debt (Notes Payable + Line of Credit) | $12,171,021 | $10,018,406 |
| Deferred Revenue (Total) | $56,345,564 | $50,891,353 |
Note: Total Debt includes $3,520,000 in line of credit and $8,651,021 in note payable (net of issuance costs).
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with a net income of $402,095, compared to a net loss of $9.5 million in 2023. This improvement was primarily driven by the absence of a $13.1 million impairment charge on Duke University license assets and a $3.7 million impairment on public inventory recorded in 2023.
- Revenue Growth: Total revenue increased 2% to $32.0 million. Processing and storage fees rose 4% due to recurring annual storage fees, offsetting a 6% decline in new domestic cord blood specimens processed.
- Expense Management: Cost of sales decreased 5% to $7.9 million. However, Selling, General, and Administrative (SG&A) expenses increased 8% to $18.5 million, and Research & Development expenses rose to $1.2 million.
- Asset Impairments: Unlike the prior year, no impairment charges were recorded for Duke assets or public inventory in 2024. However, a $308,000 impairment was recorded for the Tianhe stock investment.
- Dividends: The company declared and paid a cash dividend of $0.25 per share ($2.0 million total) in late 2024, funded by its revolving line of credit.
Guidance, Outlook, Risks, and Contingencies
- Duke University Arbitration: On October 4, 2024, Cryo-Cell filed an arbitration demand against Duke University alleging breach of contract and fraudulent inducement regarding a 2021 license agreement. Cryo-Cell seeks damages exceeding $100 million. Duke has filed counterclaims. The outcome is uncertain and could materially impact the company's financial position.
- Strategic Initiatives on Hold: Due to the Duke dispute, the planned opening of the Cryo-Cell Institute for Cellular Therapies and the proposed spinoff of the subsidiary Celle Corp. are currently on pause. The company does not anticipate further investment in Duke-related activities beyond a $350,000 comparability study until the dispute is resolved.
- Liquidity: Management believes cash, marketable securities, and operating cash flows are sufficient to fund operations for the next 12 months. However, future capital needs depend on the resolution of the Duke arbitration and potential funding requirements for clinical trials or clinic startups.
- Legal Proceedings: A class action lawsuit regarding advertising claims (Lindsey Lehr v. Cryo-Cell) was converted to individual arbitration, with a final hearing scheduled for September 2025.
- Market Risks: The company faces risks related to market acceptance of stem cell storage, competition from public banks, and potential delisting from NYSE American if listing standards are not met.
Key Facts for Investor Verification
- Arbitration Status: Verify the current status of the arbitration against Duke University and the potential financial exposure of the $100 million+ claim versus Duke's counterclaims.
- Revenue Quality: Confirm the sustainability of the 4% increase in recurring storage fees given the 6% decline in new specimen processing.
- Debt Covenants: Review the company's compliance with debt covenants (Leverage Ratio < 3.50:1 and Debt Service Coverage Ratio > 1.25:1) under the Susser Bank credit agreement.
- Dividend Sustainability: Assess the long-term viability of the new dividend policy given the company's historical accumulated deficit and reliance on debt financing for the recent payout.
- Inventory Valuation: Monitor the valuation of the public cord blood inventory ($5.3 million), which previously required significant impairment charges.